NCT04236531

Brief Summary

Source-monitoring is a cognitive process that refers to the ability to remember the source of an information. Some studies have showed source-monitoring deficits in patients with schizophrenia as well as in individuals at ultra-high risk for psychosis (UHR) and in first-episode psychosis patients (FEP). Source-monitoring deficits have thus been proposed as a potential early risk factor for psychosis. However, further studies are needed to better characterize this deficit. The aim of this project is to investigate source-monitoring performances in UHR, FEP patients and healthy controls (HC) and to characterize these deficits in terms of brain anatomy, basic auditory processes and social functioning.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
90

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started May 2021

Typical duration for not_applicable

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 6, 2020

Completed
16 days until next milestone

First Posted

Study publicly available on registry

January 22, 2020

Completed
1.3 years until next milestone

Study Start

First participant enrolled

May 17, 2021

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2023

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2024

Completed
Last Updated

March 24, 2022

Status Verified

March 1, 2022

Enrollment Period

2.4 years

First QC Date

January 6, 2020

Last Update Submit

March 23, 2022

Conditions

Keywords

source-monitoringat-riskMRIneuroimaging

Outcome Measures

Primary Outcomes (1)

  • Source-monitoring performances

    Scores obtained at a source-monitoring task (Brunelin et al., 2006)

    one day

Secondary Outcomes (6)

  • Confidence in source-monitoring judgements

    one day

  • Grey matter volume

    one day

  • Brain gyrification

    one day

  • Basic auditory performances

    one day

  • Working memory performances

    one day

  • +1 more secondary outcomes

Study Arms (3)

individuals at ultra-high risk for psychosis (UHR)

EXPERIMENTAL

30 individuals meeting the UHR criteria according to the "Comprehensive Assessment of at-risk mental state" (CAARMS) will be recruited and will complete cognitive task and MRI scan

Other: Cognitive tests and neuroimaging

patients with first episode psychosis (FEP)

EXPERIMENTAL

30 patients with first episode psychosis (FEP) will be recruited and will complete cognitive task and MRI scan

Other: Cognitive tests and neuroimaging

healthy controls

SHAM COMPARATOR

30 healthy individuals will be recruited and will complete cognitive task and MRI scan

Other: Cognitive tests and neuroimaging

Interventions

comparison of cognitive performances and brain anatomy

healthy controlsindividuals at ultra-high risk for psychosis (UHR)patients with first episode psychosis (FEP)

Eligibility Criteria

Age18 Years - 30 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Men and Women aged between 18 and 30
  • Having given their written informed consent
  • French speakers and readers
  • Absence of hearing impairments (or tinnitus) that could prevent the successful completion of tasks involving listening to sounds or words
  • Absence of visual impairments that could prevent the successful completion of tasks involving reading on the screen
  • For the healthy control group, no history of previous diagnosed psychiatric disorders (according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders - DSM5), absence of relatives diagnosed with spectrum disorder schizophrenia and bipolar disorder (DSM5), absence of psychotic prodromes measured by a score of less than 6 in the "prodromal questionnaire" - PQ-16 (Ising et al., 2012), absence of drug treatments (except oral contraception).
  • For the UHR group, meeting the UHR criteria according to the "Comprehensive Assessment of at-risk mental state" (CAARMS).
  • For the FEP group, presenting with daily psychotic symptoms for at least a week.

You may not qualify if:

  • Do not consent to be included in the study
  • Contraindication to MRI scan
  • History of neurological disease
  • Pregnancy
  • Being under tutorship or curatorship
  • Having developed musical abilities (that is, regularly practicing a musical instrument)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Centre Hospitalier le Vinatier

Bron, 69678, France

NOT YET RECRUITING

Centre Hospitalier le Vinatier

Bron, 69678, France

RECRUITING

MeSH Terms

Conditions

Psychotic Disorders

Interventions

Neuropsychological TestsNeuroimaging

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic DisordersMental Disorders

Intervention Hierarchy (Ancestors)

Psychological TestsBehavioral Disciplines and ActivitiesDiagnostic ImagingDiagnostic Techniques and ProceduresDiagnosisDiagnostic Techniques, NeurologicalInvestigative Techniques

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Model Details: Three groups of participants will be recruited: individuals at ultra-high risk for psychosis, first-episode psychosis patients and healthy controls.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 6, 2020

First Posted

January 22, 2020

Study Start

May 17, 2021

Primary Completion

October 1, 2023

Study Completion

January 1, 2024

Last Updated

March 24, 2022

Record last verified: 2022-03

Locations